Potential Deoxycytidine Kinase Inhibitory Activity of Amaryllidaceae Alkaloids: An Approach

Overview

Journal J Pharm Bioallied Sci

Specialty Pharmacology

Date 2018 Sep 22

PMID 30237684

Citations 2

Authors

Bashir A Yousef

Amina I Dirar

Mohamed Ahmed A Elbadawi

Mohamed K Awadalla

Magdi A Mohamed

Affiliations

Soon will be listed here.

Abstract

Background: Plants of the Amaryllidaceae family have been under intense scrutiny for the presence of a couple of alkaloidal secondary metabolites with endued cytotoxic activity, such as pancratistatin (), 7-deoxypancratistatin (), narciclasine (), 7-deoxynarciclasine (), -dihydronarciclasine (), and 7-deoxy--dihydronarciclasine (). Nevertheless, preclinical evaluation of these alkaloids has been put on hold because of the limited quantity of materials available from isolation.

Aim: To explore the underlying cytotoxic molecular mechanisms of the Amaryllidaceae alkaloids () and to assess their absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles using chemoinformatic tools.

Materials And Methods: AutoDock 4.0 software along with different chemoinformatic tools, namely PharmMapper, Molinspiration, MetaPrint2D, and admetSAR servers, were used to assess the drugability of the Amaryllidaceae alkaloids ().

Results: Deoxycytidine kinase (dCK) (PDB: 1P60) was predicted as a potential target with fitting score of 5.574. In silico molecular docking of () into dCK revealed good interactions, where interesting hydrogen bonds were observed with the amino acid residues-Gly-28 and Ser-35-located in the highly conserved P-loop motif. This motif plays a special role in dCK function. Contrary to (), pharmacokinetic results have shown good absorption and permeation and thus good oral bioavailability for ().

Conclusion: The docking data have proposed that the reported cytotoxic activity of the Amaryllidaceae alkaloids () could be mediated through dCK inhibition. In addition, the ADMET profile of these alkaloids is promising and thus () could be candidates for future drug development.

Citing Articles

Unveiling the Anticancer Potential: Computational Exploration of Nitrogenated Derivatives of (+)-Pancratistatin as Topoisomerase I Inhibitors.

Mohamed M, Elsaman T, Elderdery A, Alsrhani A, Ghanem H, Alruwaili M Int J Mol Sci. 2024; 25(19).

PMID: 39409108 PMC: 11476810. DOI: 10.3390/ijms251910779.

Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.

Gowrishankar S, Muthumanickam S, Kamaladevi A, Karthika C, Jothi R, Boomi P Food Chem Toxicol. 2021; 148:111966.

PMID: 33412235 PMC: 7780060. DOI: 10.1016/j.fct.2020.111966.

References

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

Pandey S, Kekre N, Naderi J, McNulty J . Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artif Cells Blood Substit Immobil Biotechnol. 2005; 33(3):279-95. DOI: 10.1081/bio-200066621. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

Palleria C, Di Paolo A, Giofre C, Caglioti C, Leuzzi G, Siniscalchi A . Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2014; 18(7):601-10. PMC: 3897029. View

Toy G, Austin W, Liao H, Cheng D, Singh A, Campbell D . Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A. 2010; 107(12):5551-6. PMC: 2851816. DOI: 10.1073/pnas.0913900107. View

Evidente A, Kireev A, Jenkins A, Romero A, Steelant W, Van Slambrouck S . Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design. Planta Med. 2009; 75(5):501-7. PMC: 3125136. DOI: 10.1055/s-0029-1185340. View

Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G . admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012; 52(11):3099-105. DOI: 10.1021/ci300367a. View

Griffin C, Karnik A, McNulty J, Pandey S . Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts. Mol Cancer Ther. 2011; 10(1):57-68. DOI: 10.1158/1535-7163.MCT-10-0735. View

10.

Yang C, Lee M, Hao J, Cui X, Guo X, Smal C . Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage. Nucleic Acids Res. 2012; 40(19):9621-32. PMC: 3479177. DOI: 10.1093/nar/gks707. View

11.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

12.

Cordell G, Farnsworth N . The potential of alkaloids in drug discovery. Phytother Res. 2001; 15(3):183-205. DOI: 10.1002/ptr.890. View

13.

Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A . Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003; 10(7):513-9. DOI: 10.1038/nsb942. View

14.

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

15.

Nomme J, Li Z, Gipson R, Wang J, Armijo A, Le T . Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability. J Med Chem. 2014; 57(22):9480-94. PMC: 4255734. DOI: 10.1021/jm501124j. View

16.

Pettit G, Gaddamidi V, Herald D, Singh S, Cragg G, Schmidt J . Antineoplastic agents, 120. Pancratium littorale. J Nat Prod. 1986; 49(6):995-1002. DOI: 10.1021/np50048a005. View

17.

Murphy J, Armijo A, Nomme J, Lee C, Smith Q, Li Z . Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. J Med Chem. 2013; 56(17):6696-708. PMC: 3789385. DOI: 10.1021/jm400457y. View

18.

Ubersax J, Woodbury E, Quang P, Paraz M, Blethrow J, Shah K . Targets of the cyclin-dependent kinase Cdk1. Nature. 2003; 425(6960):859-64. DOI: 10.1038/nature02062. View

19.

Ghavre M, Froese J, Pour M, Hudlicky T . Synthesis of Amaryllidaceae Constituents and Unnatural Derivatives. Angew Chem Int Ed Engl. 2016; 55(19):5642-91. DOI: 10.1002/anie.201508227. View

20.

Havelek R, Seifrtova M, Kralovec K, Bruckova L, Cahlikova L, Dalecka M . The effect of Amaryllidaceae alkaloids haemanthamine and haemanthidine on cell cycle progression and apoptosis in p53-negative human leukemic Jurkat cells. Phytomedicine. 2013; 21(4):479-90. DOI: 10.1016/j.phymed.2013.09.005. View